NBI-1076986
/ Neurocrine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 09, 2024
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
(PRNewswire)
- "Neurocrine Biosciences, Inc...today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1076986 in healthy adult participants. NBI-1076986 is an investigational, oral, M4 subtype-selective muscarinic acetylcholine receptor antagonist for the potential treatment of movement disorders that was discovered and developed by Neurocrine Biosciences."
Trial status • CNS Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1